Lecanemab and Donanemab Combination Therapy for Alzheimer's Disease-The Cocktail May Work Even Better Together

Document Type

Article

Publication Date

Winter 2026

Institution/Department

Neurology

Journal Title

Alzheimer disease and associated disorders

MeSH Headings

Alzheimer Disease (drug therapy); Humans; Drug Therapy, Combination; Antibodies, Monoclonal, Humanized (therapeutic use); Plaque, Amyloid (drug therapy)

Abstract

Lecanemab and Donanemab are two new FDA-approved antiamyloid immunotherapies that are Alzheimer disease modifying agents. They do not work on the same target, however. While Lecanemab targets pathologic amyloid protofibrils, Donanemab targets the amyloid plaque itself intracranially. In theory, they can be administered together, as combination therapy, to produce an augmented effect. Research of the feasibility of such a combination will require bringing together competing pharmaceutical companies, which can only happen by setting a national agenda bringing together academia, pharma, the government and advocacy groups.

First Page

65

Last Page

66

Link to Full Text

Share

COinS